TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

Market Cap	$5.12B	P/E Ratio	10.85
52W High	$46.48	52W Low	$25.28
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	27.3%	52W Position	28.6%
Overall Score	46	Value Score	40
Quality Score	44	Technical Score	54

EPS Current Est	$2.89	EPS Next Est	$1.95
EPS Growth Est	-32.5%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TGTX	$31.35	-2.03%	1.14M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TGTX	$31.35	-2.0%	1.14M
3
4
5
6

TGTX

TGTX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get TG Therapeutics Inc. Data in Excel

Get TG Therapeutics Inc. Data in Excel